BP
ZBIO

Ballentine Partners’s ProShares UltraPro Short NASDAQ Biotechnology ZBIO Stock Holding History

Ballentine Partners’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-5,000
Closed -$104K – 447
2017
Q3 		$104K Buy
+5,000
New +$120K 0.01% 381

Other funds holding ZBIO

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ballentine Partners's ZBIO Position: Q4 2017 in Review

Ballentine Partners sold out of ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) in Q4 2017, closing a stake of 5,000 shares — an estimated $104K sold.

Ballentine Partners first reported a position in ZBIO in Q3 2017 and held it in 1 quarter. The position peaked at $104K in Q3 2017. 5 funds tracked by Wall St. Rank hold ZBIO as of Q4 2017.

  • Ballentine Partners reported no remaining ProShares UltraPro Short NASDAQ Biotechnology position as of Q4 2017 after selling out during the quarter.
  • Ballentine Partners sold 5,000 ProShares UltraPro Short NASDAQ Biotechnology shares in Q4 2017, an estimated $104K.
  • Ballentine Partners first reported a position in ProShares UltraPro Short NASDAQ Biotechnology in Q3 2017 and held it in 1 quarter.
  • Ballentine Partners's ProShares UltraPro Short NASDAQ Biotechnology position peaked at $104K in Q3 2017.
  • 5 funds tracked by Wall St. Rank held ProShares UltraPro Short NASDAQ Biotechnology as of Q4 2017.

Based on Ballentine Partners's 13F filing for Q4 2017, filed 2 Feb 2018.